Oxazepam
| Clinical data | |
|---|---|
| Pronunciation | /ɒkˈsæzɪpæm/ ok-SAZ-i-pam |
| Trade names | Serax, Alepam, Serepax, others |
| Addiction liability | Low–moderate |
| Routes of administration | By mouth |
| Drug class | Benzodiazepine |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 92.8% |
| Metabolism | Hepatic (glucuronidation) |
| Onset of action | 30 - 120 minutes |
| Elimination half-life | 6–9 hours |
| Duration of action | 6 - 12 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.009.161 |
| Chemical and physical data | |
| Formula | C15H11ClN2O2 |
| Molar mass | 286.71 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 205 to 206 °C (401 to 403 °F) |
| |
| |
| (verify) | |
Oxazepam is a short-to-intermediate-acting benzodiazepine. Oxazepam is used for the treatment of anxiety, insomnia, and to control symptoms of alcohol withdrawal syndrome.
It is a metabolite of diazepam, prazepam, and temazepam, and has moderate amnesic, anxiolytic, anticonvulsant, hypnotic, sedative, and skeletal muscle relaxant properties compared to other benzodiazepines.
It was patented in 1962 and approved for medical use in 1964.